Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors at 8 institutions in 3 countries.
Ian C MichelowDepartment of Pediatrics, Division of Infectious Diseases, The Warren Alpert Medical School of Brown University, Providence, RI.ORCID 0000-0002-8399-480X
Sangshin Park *Center for International Health Research, Rhode Island Hospital, Providence, RI.ORCID 0000-0003-2407-0962
Shu-Whei Tsai *Department of Pediatrics, Division of Infectious Diseases, The Warren Alpert Medical School of Brown University, Providence, RI.ORCID 0000-0002-2625-8152
Bonnie RaytaDepartment of Pediatrics, Division of Infectious Diseases, The Warren Alpert Medical School of Brown University, Providence, RI.ORCID 0000-0003-1871-5752
Charisse Flerida A PasajeDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA.ORCID 0000-0002-9780-3680
Sara NelsonDepartment of Pediatrics, Division of Infectious Diseases, The Warren Alpert Medical School of Brown University, Providence, RI.ORCID 0000-0002-3541-9640
Angela M EarlyInfectious Disease and Microbiome Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.ORCID 0000-0002-3169-2324
Anne P FroschDepartment of Medicine, Hennepin Healthcare Research Institute, University of Minnesota, Minneapolis, MN.ORCID 0000-0003-1850-8913
George AyodoKenya Medical Research Institute, Centre of Global Health Research, Kisumu, Kenya.ORCID 0000-0002-5565-2415
Dipak K RajCenter for International Health Research, Rhode Island Hospital, Providence, RI.ORCID 0000-0002-4952-2796
Christina E NixonCenter for International Health Research, Rhode Island Hospital, Providence, RI.ORCID 0000-0003-1934-958X
Christian P NixonCenter for International Health Research, Rhode Island Hospital, Providence, RI.ORCID 0000-0002-9243-5567
Sunthorn Pond-TorCenter for International Health Research, Rhode Island Hospital, Providence, RI.ORCID 0000-0002-2456-8325
Jennifer F FriedmanCenter for International Health Research, Rhode Island Hospital, Providence, RI.ORCID 0000-0001-5804-9921
Michal FriedDepartment of Pediatrics, The Warren Alpert Medical School of Brown University, Providence, RI.ORCID 0000-0002-5478-6526
Patrick E DuffyDepartment of Pediatrics, The Warren Alpert Medical School of Brown University, Providence, RI.ORCID 0000-0002-4483-5005
Karine G Le RochLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD.ORCID 0000-0002-4862-9292
Jacquin C Niles *Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA.ORCID 0000-0002-6250-8796
Jonathan D Kurtis *Center for International Health Research, Rhode Island Hospital, Providence, RI.ORCID 0000-0003-1032-9558
Brown University · USRhode Island Hospital · USMassachusetts Institute of Technology · USBroad Institute · USKenya Medical Research Institute · KENational Institutes of Health · USUniversity of Minnesota · USUniversity of Seoul · KR
Funding
Malaria Pathogenesis in young children and vaccine discoveryZIAAI001134 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DUFFY, PATRICK · 2010 to 2025
$11.3M
Statistics and Data Management P20GM104317 · NIGMS · UNIVERSITY OF RHODE ISLAND · PI MICHELOW, IAN · 2013 to 2017
$9.8M
Malaria Pathogenesis in Pregnant Women and Young ChildrenZIAAI001153 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FRIED, MICHAL · 2011 to 2025
$9.5M
Chromatin structure and control of gene expression in the human malaria parasiteR01AI136511 · NIAID · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI LE ROCH, KARINE GAELLE · 2018 to 2022
$3.4M
Emerging Infectious Disease Scholars at Brown UniversityR25AI140490 · NIAID · BROWN UNIVERSITY · PI Silvia Shinpei Chiang · 2018 to 2026
$3.0M
Memory T follicular helper cell kinetics and localization during recall immune responses to tetanus vaccinationK08AI141761 · NIAID · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI FROSCH, ANNE ELIZABETH PARKER · 2019 to 2023
$984k
Vaccine Development for Falciparum Malaria in Pregnant Women and Their OffspringK08AI100997 · NIAID · RHODE ISLAND HOSPITAL · PI MICHELOW, IAN C · 2013 to 2017
We previously identified a Plasmodium falciparum (Pf) protein of unknown function encoded by a single-copy gene, PF3D7_1134300, as a target of antibodies in plasma of Tanzanian children in a whole-proteome differential screen. Here we characterize this protein as a blood-stage antigen that localizes to the surface membranes of both parasitized erythrocytes and merozoites, hence its designation as Pf erythrocyte membrane and merozoite antigen 1 (PfEMMA1). Mouse anti-PfEMMA1 antisera and affinity-purified human anti-PfEMMA1 antibodies inhibited growth of P. falciparum strains by up to 68% in growth inhibition assays. Following challenge with uniformly fatal Plasmodium berghei (Pb) ANKA, up to 40% of mice immunized with recombinant PbEMMA1 self-cured, and median survival of lethally infected mice was up to 2.6-fold longer than controls (21 vs. 8 d, P = 0.005). Furthermore, high levels of naturally acquired human anti-PfEMMA1 antibodies were associated with a 46% decrease in parasitemia over 2.5 yr of follow-up of Tanzanian children. Together, these findings suggest that antibodies to PfEMMA1 mediate protection against malaria.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A newly characterized malaria antigen on erythrocyte and merozoite surfaces induces parasite inhibitory antibodies. · full record | OpenQuestion